PT  - JOURNAL ARTICLE
AU  - Florian Eichhorn
AU  - Hauke Winter
TI  - How to handle oligometastatic disease in nonsmall cell lung cancer
AID  - 10.1183/16000617.0234-2020
DP  - 2021 Mar 31
TA  - European Respiratory Review
PG  - 200234
VI  - 30
IP  - 159
4099  - http://err.ersjournals.com/content/30/159/200234.short
4100  - http://err.ersjournals.com/content/30/159/200234.full
SO  - EUROPEAN RESPIRATORY REVIEW2021 Mar 31; 30
AB  - Patients with nonsmall cell lung cancer and limited metastatic disease have been defined as oligometastatic if local ablative therapy of all lesions is amenable. Evidence from different clinical retrospective series suggests that this subgroup harbours better prognosis than other stage IV patients. However, most reports have included patients with inconsistent numbers of metastases in different locations treated by a variety of invasive and noninvasive therapies. As long as further results from randomised clinical trials are awaited, treatment decision follows an interdisciplinary debate in each individual case. Surgery and radiotherapy should capture a dominant role in the treatment course offering the option of a curative-intended local therapy in combination with a systemic therapy based on an interdisciplinary decision. This review summarises the current treatment standard in oligometastatic lung cancer with focus on an ablative therapy for both lung primary and distant metastases in prognostically favourable locations.Lung cancer patients with oligometastatic disease can profit from local ablative therapy of primary and all extrathoracic lesions. Treatment should follow a multidisciplinary decision and be restricted to limited brain, lung and adrenal metastases. https://bit.ly/3drd6l9